Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study

Abstract Background Aspergillus fumigatus is frequently encountered in sputum samples of patients with cystic fibrosis (CF), which traditionally has been interpreted as saprophytic airway colonization. However, this mere bystander role has been challenged by recent data. There is now evidence that A...

Full description

Bibliographic Details
Main Authors: Johannes Träger, Volker Otto Melichar, Renate Meyer, Manfred Rauh, Christian Bogdan, Jürgen Held
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12890-018-0614-8
id doaj-d4a4ab2a7292434abea5307406bdc87e
record_format Article
spelling doaj-d4a4ab2a7292434abea5307406bdc87e2020-11-24T23:59:37ZengBMCBMC Pulmonary Medicine1471-24662018-03-0118111310.1186/s12890-018-0614-8Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort studyJohannes Träger0Volker Otto Melichar1Renate Meyer2Manfred Rauh3Christian Bogdan4Jürgen Held5Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergKinder- und Jugendklinik, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergKinder- und Jugendklinik, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergMikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-NürnbergAbstract Background Aspergillus fumigatus is frequently encountered in sputum samples of patients with cystic fibrosis (CF), which traditionally has been interpreted as saprophytic airway colonization. However, this mere bystander role has been challenged by recent data. There is now evidence that Aspergillus fumigatus accelerates the decline of pulmonary function. (1→3)-β-D-glucan (BDG) and galactomannan (GM) are highly sensitive fungal biomarkers that are used to diagnose invasive fungal disease. However, their diagnostic value in CF patients is largely unknown. Methods We conducted a retrospective cohort study on 104 CF patients to determine whether serum BDG and GM levels correlate with parameters such as Aspergillus-positive sputum cultures and lung function. Results Aspergillus fumigatus was persistently detected in 22 of the 104 CF patients (21%). Mean serum BDG and GM levels in the Aspergillus-positive patients were significantly higher than in those without persistent Aspergillus detection (89 versus 40 pg/ml [p = 0.022] and 0.30 versus 0.15 ODI [p = 0.013], respectively). 27 and 7 patients had elevated BDG (≥ 60 pg/ml) or GM levels (> 0.5 ODI), respectivly. BDG and GM levels showed a significant correlation (p = 0.004). Patients with increased serum concentrations of BDG were more frequently Aspergillus-positive (40.7 versus 14.3%, p = 0.004) and had a significantly lower forced expiratory volume in one second (FEV1) than patients with a normal BDG (61.6 versus 77.1%, p = 0.007). In the multivariate analysis, BDG but not GM or the growth of A. fumigatus, proved to be an independent predictor for the FEV1. Conclusions CF patients with persistent Aspergillus detection have elevated BDG and GM levels which ranged between healthy and invasively infected patients. Serum BDG may be superior to GM and fungal culture in predicting an impaired lung function in CF patients.http://link.springer.com/article/10.1186/s12890-018-0614-8(1→3)-β-D-glucanGalactomannanBiomarkerCystic fibrosisAspergillusAllergic bronchopulmonary aspergillosis
collection DOAJ
language English
format Article
sources DOAJ
author Johannes Träger
Volker Otto Melichar
Renate Meyer
Manfred Rauh
Christian Bogdan
Jürgen Held
spellingShingle Johannes Träger
Volker Otto Melichar
Renate Meyer
Manfred Rauh
Christian Bogdan
Jürgen Held
Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
BMC Pulmonary Medicine
(1→3)-β-D-glucan
Galactomannan
Biomarker
Cystic fibrosis
Aspergillus
Allergic bronchopulmonary aspergillosis
author_facet Johannes Träger
Volker Otto Melichar
Renate Meyer
Manfred Rauh
Christian Bogdan
Jürgen Held
author_sort Johannes Träger
title Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
title_short Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
title_full Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
title_fullStr Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
title_full_unstemmed Serum (1→3)-β-D-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
title_sort serum (1→3)-β-d-glucan and galactomannan levels in patients with cystic fibrosis: a retrospective cohort study
publisher BMC
series BMC Pulmonary Medicine
issn 1471-2466
publishDate 2018-03-01
description Abstract Background Aspergillus fumigatus is frequently encountered in sputum samples of patients with cystic fibrosis (CF), which traditionally has been interpreted as saprophytic airway colonization. However, this mere bystander role has been challenged by recent data. There is now evidence that Aspergillus fumigatus accelerates the decline of pulmonary function. (1→3)-β-D-glucan (BDG) and galactomannan (GM) are highly sensitive fungal biomarkers that are used to diagnose invasive fungal disease. However, their diagnostic value in CF patients is largely unknown. Methods We conducted a retrospective cohort study on 104 CF patients to determine whether serum BDG and GM levels correlate with parameters such as Aspergillus-positive sputum cultures and lung function. Results Aspergillus fumigatus was persistently detected in 22 of the 104 CF patients (21%). Mean serum BDG and GM levels in the Aspergillus-positive patients were significantly higher than in those without persistent Aspergillus detection (89 versus 40 pg/ml [p = 0.022] and 0.30 versus 0.15 ODI [p = 0.013], respectively). 27 and 7 patients had elevated BDG (≥ 60 pg/ml) or GM levels (> 0.5 ODI), respectivly. BDG and GM levels showed a significant correlation (p = 0.004). Patients with increased serum concentrations of BDG were more frequently Aspergillus-positive (40.7 versus 14.3%, p = 0.004) and had a significantly lower forced expiratory volume in one second (FEV1) than patients with a normal BDG (61.6 versus 77.1%, p = 0.007). In the multivariate analysis, BDG but not GM or the growth of A. fumigatus, proved to be an independent predictor for the FEV1. Conclusions CF patients with persistent Aspergillus detection have elevated BDG and GM levels which ranged between healthy and invasively infected patients. Serum BDG may be superior to GM and fungal culture in predicting an impaired lung function in CF patients.
topic (1→3)-β-D-glucan
Galactomannan
Biomarker
Cystic fibrosis
Aspergillus
Allergic bronchopulmonary aspergillosis
url http://link.springer.com/article/10.1186/s12890-018-0614-8
work_keys_str_mv AT johannestrager serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
AT volkerottomelichar serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
AT renatemeyer serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
AT manfredrauh serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
AT christianbogdan serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
AT jurgenheld serum13bdglucanandgalactomannanlevelsinpatientswithcysticfibrosisaretrospectivecohortstudy
_version_ 1725447144655028224